A process for the separation of 177Lu from neutron irradiated 176Yb targets

Horwitz, E. P.; McAlister, Daniel R.; Bond, A.; Barrans, Richard E.; Williamson, J.M.

doi:10.1016/j.apradiso.2005.02.005

Cited by 97 publications

(42 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The aforementioned EXC technique was further exploited by Horwitz et al and culminated in a conceptual flow sheet that was found to be successful for the separation of NCA 177 Lu from a 300-mg irradiated ytterbium target [68]. The process is essentially based on the use of two different EXC resins, namely a resin containing HEH[EHP] (LN2) and a resin containing tetraoctyl diglycolamide (DGA) sorbed onto Amberchrom® CG-71.…”

Section: Extraction Chromatographymentioning

confidence: 99%

See 1 more Smart Citation

Production of 177Lu for Targeted Radionuclide Therapy: Available Options

Dash

Pillai²,

Knapp

2015

Nucl Med Mol Imaging

243

166

View full text Add to dashboard Cite

Background: This review provides a comprehensive summary of the production of 177 Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of 177 Lu having the required quality for preparation of a variety of 177 Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of 177 Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success. Methods: While both "direct" and "indirect" reactor production routes offer the possibility for sustainable 177 Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies. Results: This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future. Conclusion: A broad understanding and discussion of the issues associated with 177 Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of 177 Lu-labeled radiopharmaceuticals, but also help future developments.

show abstract

Section: Extraction Chromatographymentioning

confidence: 99%

“…8 Secondary NCA 177 Lu separation step [68]. This process is essential for removing adventitious impurities from the 177 Lu Fig.…”

Section: Cementation Processmentioning

confidence: 99%

Production of 177Lu for Targeted Radionuclide Therapy: Available Options

Dash

Pillai²,

Knapp

2015

Nucl Med Mol Imaging

243

166

View full text Add to dashboard Cite

show abstract

“…In addition due to required material and equipment, this method is cost‐effective. A conceptual flowsheet was developed for the separation of 177 Lu/ 176 Yb by Horwitz et al (27) that is the base of separation in this work. EXC, as a separation strategy, is a combination of the liquid–liquid extraction and column chromatography; it also gains the selectivity and the rapidity of liquid–liquid extraction and column chromatography, respectively.…”

Section: Resultsmentioning

confidence: 99%

“…Formation of a small amounts of long‐lived 177 mLu

false({normalt}_{1 / 2} = 160.5 d false)

is the main drawback of the direct route. Using this method, the product will also contain macro quantities of nonradioactive isotopes of Lu and, consequently, has a comparatively low specific activity 27 , 28 . With the indirect route, it is feasible to separate 177 Lu from 176 Yb due to their chemical differences, which leads to produce a “no‐carrier‐added” (NCA) therapeutic radioisotope of 177 Lu without any nonradioactive isotope.…”

Section: Introductionmentioning

confidence: 99%

“…Many researchers reported separation of NCA 177 Lu from Yb target by different methods 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 . In this study, NCA 177 Lu is separated from 176 Yb target by extraction chromatography (EXC).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Production and quality control ¹⁷⁷Lu (NCA)—DOTMP as a potential agent for bone pain palliation

Salek

Shamsaei

Maragheh

et al. 2016

J Applied Clin Med Phys

View full text Add to dashboard Cite

Skeletal uptake of radiolabeled‐1, 4, 7, 10‐tetraazacyclododecane‐1, 4, 7, 10‐tetramethylene phosphoric acid (e.g., 177Lu‐DOTMP) complex, is used for bone pain palliation. The moderate energy of β‐emitting .15em177Lu false(normalT1/2=6.7 d,normalEβmax=497 keVfalse) has been considered as a potential radionuclide for development of the bone‐seeking radiopharmaceutical. Since the specific activity of the radiolabeled carrier molecules should be high, the “no‐carrier‐added radionuclides” have significant roles in nuclear medicine. Many researchers illustrated no‐carrier‐added 177Lu production; among these separation techniques such as ion exchange chromatography, reversed phase ion‐pair, and electrochemical method, extraction chromatography has been considered more capable than other methods. In order to optimize the conditions, some effective factors on separation of Lu/Yb were investigated by EXC. The NCA 177Lu, produced by this method, was mixed with 300μ1 of DOTMP solution (20 mg in 1 mL of 0.5 M NaHCO3, pH=8) and incubated under stirring at room temperature for 45 min. Radiochemical purity of the 177Lu‐DOTMP complex was determined using radio‐thin‐layer chromatography (RTLC) method. The complex was injected to wild‐type rats and biodistribution was then studied for seven days. The NCA 177Lu was produced with specific activity of 48 Ci/mg and with a radinuclidic purity of 99.99% through irradiation of enriched 176Yb target (1 mg) in a thermal neutron flux of 4×1013 n.cm−2.normals−1 for 14 days. 177Lu‐DOTMP was obtained with high radiochemical purities (>98%) under optimized reaction conditions. The radiolabeled complex exhibited excellent stability at room temperature. Biodistribution of the radiolabeled complex studies in rats showed favorable selective skeletal uptake with rapid clearance from blood along with insignificant accumulation within the other nontargeted organs.PACS number(s): 87.57.un, 87.57.uq

show abstract

Production, quality control, and determination of human absorbed dose of no carrier added ¹⁷⁷Lu‐risedronate for bone pain palliation therapy

Salek

Mehrabi

Arani

et al. 2016

Labelled Comp Radiopharmac

View full text Add to dashboard Cite

In this study, the radiocomplexation of risedronic acid, a potent bisphosphonate with a no carrier added (NCA) Lu, was investigated and followed by quality control studies, biodistribution evaluation, and dosimetry study for human based on biodistribution data in Wistar rats. The moderate energy β emitter, Lu (T = 6.7 days, E = 497 keV), has been considered as a potential agent for development of bone-seeking radiopharmaceuticals. Because the specific activity of the radiolabeled carrier molecules should be high, the NCA radionuclides have an effective role in nuclear medicine. Many researchers illustrated an NCA Lu production; among these separation techniques, extraction chromatography has been considered more capable than other methods. The NCA Lu was produced with specific activity of 48 Ci/mg and radionuclidic purity of 99.99% by the irradiation of enriched Yb target in thermal neutron flux of 4 × 10 n·cm ·s for 14 days. The NCA Lu was mixed to a desired amount of sodium risedronate (15 mg/mL, 200 μL) and incubated with stirring at 95°C for 30 minutes. The radiochemical purity of Lu-risedronate was determined by radio thin-layer chromatography, and high radiochemical purities (>97%) were obtained under optimized reaction conditions. The complex was injected to Wistar rats, and complex biodistribution was performed 4 hours to 7 days postinjections showing high bone uptake (9.8% ± 0.24% ID/g at 48 hours postinjection). Also, modeling the radiation dose delivery by RADAR software for the absorbed dose evaluation of each human organ showed a major accumulation of the radiocomplex in bone tissue.

show abstract

A process for the separation of 177Lu from neutron irradiated 176Yb targets

Cited by 97 publications

References 11 publications

Production of 177Lu for Targeted Radionuclide Therapy: Available Options

Production of 177Lu for Targeted Radionuclide Therapy: Available Options

Production and quality control ¹⁷⁷Lu (NCA)—DOTMP as a potential agent for bone pain palliation

Production, quality control, and determination of human absorbed dose of no carrier added ¹⁷⁷Lu‐risedronate for bone pain palliation therapy

Contact Info

Product

Resources

About

A process for the separation of 177Lu from neutron irradiated 176Yb targets

Cited by 97 publications

References 11 publications

Production of 177Lu for Targeted Radionuclide Therapy: Available Options

Production of 177Lu for Targeted Radionuclide Therapy: Available Options

Production and quality control 177Lu (NCA)—DOTMP as a potential agent for bone pain palliation

Production, quality control, and determination of human absorbed dose of no carrier added 177Lu‐risedronate for bone pain palliation therapy

Contact Info

Product

Resources

About

Production and quality control ¹⁷⁷Lu (NCA)—DOTMP as a potential agent for bone pain palliation

Production, quality control, and determination of human absorbed dose of no carrier added ¹⁷⁷Lu‐risedronate for bone pain palliation therapy